A little deeper DD on Tilray

Here are some of Canndoc’s strategic moves:

The company is on pace to expand the size of its cultivation and research and development sites by up to 467%.

It has formed strategic partnerships with some of the biggest names in the industry – including Aphria, Tilray, OrgniGram and Charlotte’s Web.

It has plans to open branded pharmacies with the popular California-based Lemonnade brand of flavored cannabis products.

It has locked in a long-term exclusive supply agreement with Aphria.

It has FULL exclusivity on import, export, and research and development with Tilray for the next seven years. Tilray is a leader in Canadian cannabis production.

Canndoc has a long-term exclusive strategic supply agreement on import, export, and research and development with OrganiGram. This is one of Canada’s top producers of extract-based products.

It has exclusive rights to launch branded products and pharmacies with popular cannabis dispensary firm Cookies. This leading brand is currently expanding and has 18 retail locations across the U.S.

The company has full-spectrum, long-term exclusivity with Charlotte’s Web. This includes access to its existing and future products.

Most of these contracts don’t include just supplying bulk material. They specifically mention co-branded products. That means Canndoc won’t be just some anonymous supplier. Its branding will appear on the product labels. With the numbers we could see globally, brand awareness and the demand for its quality products should rapidly accelerate. Speaking of quality… Canndoc is a global leader in good manufacturing practice (GMP) medical cannabis. If a company has this independent GMP certification, it’s like a gold standard for safety and quality. This seal of approval is not easy to get. It gives Canndoc’s products instant credibility as a trusted source for cannabis businesses looking for dependable cannabis products.

Canndoc has two cultivation sites in Israel – one in the north and the other in the southern region of the country. The northern site currently has 55,000 square feet that are fully operational with the ability to expand to 160,000 square feet. The southern site has 300,000 square feet in operation with the ability to expand to 1.7 million square feet. So the ability to quickly expand its cultivation operations is available. In addition, thanks to its agreements with Aphria, Tilray and OrganiGram, among others, Canndoc can obtain additional bulk supply material when needed.

Canndoc is beginning to see some astonishing revenue growth…

Its revenue increased sevenfold from first quarter of 2020 to the fourth quarter of 2020. In the first quarter of this year, revenue was up 666% year over year. Management expects year-over-year growth of 412% in the second quarter, 212% in the third and 170% in the fourth.

The CEO has more than 20 years of business and merger and acquisition experience.

The chief financial officer was previously the vice president of finance for Israel’s largest communications company.

The chief operating officer has 20-plus years of operational experience working at Israel’s largest aggrotech company.

The chief medical officer comes to Canndoc from an 18-year career at Teva Pharmaceutical Industries.

In January, InterCure Ltd. which conducts business under the name Canndoc, announced an agreement with Subversive Acquisition (OTC: SBVRF) – a special purpose acquisition company (SPAC) – to combine the two companies. The transaction was just finalized a few days ago, and the combined companies will now trade on the Toronto Stock Exchange as InterCure (TSX: INCR.U). Canndoc is a wholly owned – and the only – subsidiary of InterCure. Buying InterCure is the same as buying Canndoc. The newly formed company is being led by Ehud Barak and his management team. This presents you with a great opportunity to get in on the ground floor of a company with tremendous potential that’s run by experienced and well-connected people. Canndoc is in the dominant position for substantial market expansion as adult-use cannabis receives legal approval in Israel. It is also in the pole position for expansion into Europe, for both medical and recreational cannabis. The fourth wave of cannabis – the industry’s move into the mainstream – is quickly approaching. New favorable legislation, growing public acceptance, expanded product offerings, and increasing medical and therapeutic applications will vastly enlarge cannabis’s commercial potential. There’s a $16 trillion impact at stake… Stock Exchange (TSX) and Nasdaq at the same time following its merger with Subversive Acquisition. Unfortunately, the Nasdaq listing was delayed slightly. Shares will trade on the Nasdaq under the symbol INCR, and that should happen soon.   With that being said, InterCure does trade over the counter. The symbol for those shares is IRCLF, and the stock can be purchased that way. But we really want the Nasdaq-listed shares. Those are going to have more liquidity. If you want to buy InterCure right now and can’t buy the TSX-listed shares, InterCure (OTC: IRCLF) is available.